Shirin Shirani, MD
Nephrology · New Haven, CTNPI 1891781191
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 94.8% of the total across 90 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 23 manufacturers reported payments, led by Vifor Pharma, Inc. at 29.4% of the total. Reporting peaked in 2019 at $674 and has fallen 73.6% since, to $178 in 2025.
Across 90 payments — averaging $23.22 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Vifor Pharma, Inc.$614
- AstraZeneca$305
- Amgen$300
- Otsuka America Pharmaceutical, Inc.$159
- GSK$68
- Boehringer Ingelheim$63
- plus $582 from 17 others
What the payments were for
- Food & beverage$1,98295%
- Education$1085%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Vifor Pharma, Inc. | 22 | $614 |
| AstraZeneca(2 entities) | 14 | $305 |
| Amgen(2 entities) | 12 | $300 |
| Otsuka America Pharmaceutical, Inc. | 6 | $159 |
| GSK | 4 | $68 |
| Boehringer Ingelheim | 2 | $63 |
| Fresenius USA Marketing, Inc. | 3 | $61 |
| Ardelyx, Inc. | 3 | $59 |
| Genentech USA, Inc. | 4 | $58 |
| Aurinia Pharma U.S., Inc. | 2 | $52 |
| Akebia Therapeutics Inc | 2 | $51 |
| Travere Therapeutics, Inc. | 3 | $47 |
| Novartis | 2 | $44 |
| Xeris Pharmaceuticals, Inc. | 2 | $33 |
| OPKO Pharmaceuticals, LLC | 1 | $28 |
| Bayer | 1 | $24 |
| Novo Nordisk | 1 | $23 |
| Sanofi | 1 | $21 |
| Calliditas Therapeutics US Inc. | 1 | $19 |
| Bard Peripheral Vascular, Inc. | 1 | $17 |
| Kyowa Kirin, Inc. | 1 | $17 |
| E.r. Squibb & Sons, L.L.C. | 1 | $15 |
| Johnson & Johnson | 1 | $12 |
How this compares
$2,090 in reported general payments places this provider in the 70th percentile of 144 nephrology providers in Connecticut.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| VelphoroSucroferric Oxyhydroxide | 25 | $59,281 |
| EliquisApixaban | 12 | $10,525 |
| LokelmaSodium Zirconium Cyclosilicate | 11 | $9,485 |
| Sevelamer Carbonate | 58 | $7,598 |
| Allopurinol | 50 | $983 |
| Lidocaine-PrilocaineLidocaine/Prilocaine | 16 | $523 |
| Calcium Acetate | 14 | $485 |
| Furosemide | 37 | $383 |
| Hydrochlorothiazide | 33 | $206 |
| Lisinopril | 35 | $176 |
| Amlodipine Besylate | 15 | $116 |
| Losartan Potassium | 15 | $101 |
| Pantoprazole Sodium | 11 | $78 |
| Ezetimibe | 14 | $28 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Fresenius USA Marketing, Inc.Velphoro | $61 | $59,28125 claims |
| AstraZenecaLokelma | $305 | $9,48511 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 144 nephrology providers in Connecticut.
Other nephrology in New Haven
- Robert AlpernNew Haven$4.9M
- Richard FormicaNew Haven$198K
- Stefan SomloNew Haven$111K
- Fredric FinkelsteinNew Haven$70K
- Justin BelcherNew Haven$59K
- Ladan GolestanehNew Haven$54K
- Aldo PeixotoNew Haven$17K
- Ali Abu-AlfaNew Haven$16K
- Lloyd CantleyNew Haven$14K
- Sue ChangNew Haven$9K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.